LYEL — Lyell Immunopharma Balance Sheet

0.000.00%

Last trade - 00:00

HealthcareSpeculativeMid CapNeutral

Annual balance sheet for Lyell Immunopharma, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

	2019 December 31st	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st
Period Length:	—	—	—	—	—
Source:	PROSPECTUS	PROSPECTUS	10-K	10-K	10-K
Standards:	USG	USG	USG	USG	USG
Status:	Final	Final	Final	Final	Final
Cash and Equivalents
Short Term Investments
Cash and Short Term Investments	436	613	615	640	546
Prepaid Expenses
Total Current Assets	440	618	626	651	555
Gross Property, Plant And Equipment
Accumulated Depreciation
Net Property, Plant And Equipment	43.7	124	167	166	142
Long Term Investments
Other Long Term Assets
Total Assets	556	908	1,127	938	750
Accounts Payable
Accrued Expenses
Notes Payable / Short Term Debt
Total Other Current Liabilities
Total Current Liabilities	22	49.3	46.7	37	34.5
Total Long Term Debt
Total Debt
Total Other Liabilities
Total Liabilities	148	190	198	104	95.1
Redeemable Preferred Stock
Common Stock
Additional Paid In Capital
Retained Earnings (Accumulated Deficit)
Other Equity
Total Equity	408	718	930	833	655
Total Liabilities & Shareholders' Equity	556	908	1,127	938	750
Total Common Shares Outstanding